Dantron

Dantron
Clinical data
Routes of
administration		 Oral, rectal (enema)
ATC code A06AB03 (WHO) A06AG03 (WHO)
Identifiers
CAS Number 117-10-2 YesY
PubChem (CID) 2950
DrugBank DB04816 N
ChemSpider 2845 YesY
UNII Z4XE6IBF3V N
KEGG D07107 N
ChEBI CHEBI:3682 N
ChEMBL CHEMBL53418 N
NIAID ChemDB 001375
ECHA InfoCard 100.003.794
Chemical and physical data
Formula C14H8O4
Molar mass 240.211 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Dantron (INN), also known as chrysazin or 1,8-dihydroxyanthraquinone, is an organic substance, formally derived from anthraquinone by the replacement of two hydrogen atoms by hydroxyl groups (–OH). It is used in some countries as a stimulant laxative.

It should not be confused with ondansetron, an unrelated drug that was marketed in South Africa under the trade name "Dantron".

Medical uses

In the USA, dantron is not used because it is considered to be a carcinogen.[1]

In the UK it is considered a possible carcinogen and so its licence is restricted to patients who already have a diagnosis of terminal cancer. It is mainly used in palliative care to counteract the constipating effects of opioids. Its British Approved Name was danthron, but it has now been changed to "dantron", the recommended International Nonproprietary Name.[2]

Dantron has the notable side-effect of causing red-colored urine.

See also

References

  1. ↑ Danthron substance profile at the National Toxicology Program website
  2. ↑ British National Formulary website (requires free registration)


This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.